Financial reports
ARS
2023 FY
Annual report to shareholders
16 Apr 24
10-K
2023 FY
Annual report
12 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
ARS
2022 FY
Annual report to shareholders
19 Apr 23
10-K
2022 FY
Annual report
10 Feb 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
27 Jul 22
10-Q
2022 Q1
Quarterly report
3 May 22
Current reports
8-K
Regulation FD Disclosure
18 Apr 24
8-K
Results of Operations and Financial Condition
31 Jan 24
8-K
2023 revenues outlook revised to $15.1 - $15.5 billion from $15.0 - $15.4 billion
8 Nov 23
8-K
Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment
4 Oct 23
8-K
Teva Announces Changes to Executive Management Team
28 Sep 23
8-K
Entry into a Material Definitive Agreement
24 Aug 23
8-K
Departure of Directors or Certain Officers
2 Aug 23
8-K
Results of Operations and Financial Condition
2 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 23
8-K
Teva Concludes Nationwide Opioids Settlement Agreement
8 Jun 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
3 Mar 23
FWP
Free writing prospectus
1 Mar 23
424B5
Prospectus supplement for primary offering
27 Feb 23
F-6EF
Automatic registration for ADRs (foreign)
8 Feb 23
424B5
Prospectus supplement for primary offering
4 Nov 21
FWP
Free writing prospectus
2 Nov 21
424B3
Prospectus supplement
27 Oct 21
S-3ASR
Automatic shelf registration
27 Oct 21
424B3
Prospectus supplement
17 Aug 20
S-4
Registration of securities issued in business combination transactions
5 Aug 20
Proxies
DEFA14A
Additional proxy soliciting materials
16 Apr 24
DEF 14A
Definitive proxy
16 Apr 24
DEFA14A
Additional proxy soliciting materials
24 May 23
DEFA14A
Additional proxy soliciting materials
19 Apr 23
DEF 14A
Definitive proxy
19 Apr 23
DEFA14A
Additional proxy soliciting materials
13 Apr 22
DEF 14A
Definitive proxy
13 Apr 22
PRE 14A
Preliminary proxy
15 Mar 22
DEFA14A
Additional proxy soliciting materials
21 Apr 21
DEF 14A
Definitive proxy
21 Apr 21
Other
SD
Conflict minerals disclosure
24 May 23
UPLOAD
Letter from SEC
21 Dec 22
CORRESP
Correspondence with SEC
20 Dec 22
UPLOAD
Letter from SEC
1 Dec 22
CORRESP
Correspondence with SEC
26 Oct 22
UPLOAD
Letter from SEC
13 Sep 22
SD
Conflict minerals disclosure
25 May 22
SD
Conflict minerals disclosure
20 May 21
UPLOAD
Letter from SEC
21 Apr 21
CORRESP
Correspondence with SEC
15 Apr 21